Srijana Bakshi, MD
Rheumatology · Okemos, MINPI 1972764520
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (51.0%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. 34 manufacturers reported payments, led by Amgen at 46.0% of the total.
Across 1,109 payments — averaging $30.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$16K
- Johnson & Johnson$5K
- UCB, Inc.$3K
- AbbVie$3K
- Novartis$1K
- Mallinckrodt Hospital Products Inc.$1K
- plus $5K from 28 others
Across 20 payments — averaging $13,067 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$206K
- Eli Lilly$50K
- Janssen Research & Development, LLC$5K
- E.r. Squibb & Sons, L.L.C.$341
What the payments were for
- Consulting fees$5,76817%
- Speaking & faculty fees$8,89026%
- Grants$2401%
- Travel & lodging$1,3784%
- Food & beverage$17,43751%
- Education$4481%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 313 | $15,724 |
| Johnson & Johnson(2 entities) | 154 | $5,002 |
| UCB, Inc. | 95 | $3,091 |
| AbbVie | 160 | $2,764 |
| Novartis | 70 | $1,397 |
| Mallinckrodt Hospital Products Inc. | 9 | $1,150 |
| Pfizer | 77 | $891 |
| E.r. Squibb & Sons, L.L.C. | 62 | $775 |
| AstraZeneca(2 entities) | 28 | $562 |
| Lilly USA, LLC | 22 | $448 |
| ANI Pharmaceuticals, Inc. | 16 | $365 |
| Genentech USA, Inc. | 19 | $328 |
| Sanofi | 16 | $270 |
| GSK | 13 | $227 |
| Boehringer Ingelheim | 6 | $142 |
| Radius Health, Inc. | 7 | $129 |
| Organon | 6 | $116 |
| Aurinia Pharma U.S., Inc. | 5 | $110 |
| Sobi, Inc | 5 | $108 |
| Regeneron Healthcare Solutions, Inc. | 4 | $95 |
| Actelion Pharmaceuticals US, Inc. | 2 | $56 |
| Sandoz | 2 | $55 |
| Tonix Medicines, Inc. | 2 | $49 |
| Fresenius Kabi USA, LLC | 2 | $46 |
| Mallinckrodt Enterprises LLC | 2 | $42 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $40 |
| Invivyd Inc | 2 | $32 |
| Kyowa Kirin, Inc. | 2 | $31 |
| Octapharma USA, Inc. | 1 | $23 |
| Bristol Myers Squibb | 1 | $21 |
| Pacira Therapeutics, Inc. | 1 | $21 |
| Biocon Biologics Inc | 1 | $19 |
| Alvogen Inc | 1 | $19 |
| Antares Pharma, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$34,160 in reported general payments places this provider in the 85th percentile of 195 rheumatology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 97 | $964,690 |
| OtezlaApremilast | 105 | $517,098 |
| Enbrel SureclickEtanercept | 47 | $344,147 |
| Taltz AutoinjectorIxekizumab | 35 | $321,096 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 35 | $261,010 |
| Skyrizi PenRisankizumab-Rzaa | 11 | $246,870 |
| Enbrel MiniEtanercept | 27 | $211,340 |
| RinvoqUpadacitinib | 26 | $198,431 |
| Cosentyx Sensoready PenSecukinumab | 22 | $183,356 |
| BenlystaBelimumab | 23 | $165,014 |
| Humira PenAdalimumab | 14 | $130,918 |
| XeljanzTofacitinib Citrate | 20 | $111,149 |
| Orencia ClickjectAbatacept | 12 | $86,648 |
| Humira(Cf)Adalimumab | 13 | $85,003 |
| MethotrexateMethotrexate Sodium | 327 | $15,382 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenOtezla | $15,724 | $517,098105 claims |
| AbbVieRinvoq, Humira(Cf) | $2,764 | $283,43439 claims |
| GSKBenlysta | $227 | $165,01423 claims |
| PfizerXeljanz | $891 | $111,14920 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 195 rheumatology providers in Michigan.
Other rheumatology in Okemos
- Monika MohanOkemos$127K
- Amar MajjhooSaint Clair Shores$1.8M
- Andrew SulichSaint Clair Shores$1.7M
- Dinesh KhannaAnn Arbor$1.2M
- Roman CzubatyjRochester Hills$764K
- Delfin SantosRochester$242K
- Allan MortonWarren$229K
- Elena SchiopuAnn Arbor$180K
- Alireza MeysamiNovi$170K
- Fazleomar MahmoodChelsea$167K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.